Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) EBT (2023 - 2025)

Immunocore Holdings' EBT history spans 3 years, with the latest figure at -$15.8 million for Q4 2025.

  • For Q4 2025, EBT rose 36.37% year-over-year to -$15.8 million; the TTM value through Dec 2025 reached -$19.1 million, up 63.92%, while the annual FY2025 figure was -$19.1 million, 63.92% up from the prior year.
  • EBT for Q4 2025 was -$15.8 million at Immunocore Holdings, down from $304000.0 in the prior quarter.
  • Across five years, EBT topped out at $6.1 million in Q3 2024 and bottomed at -$25.6 million in Q4 2023.
  • The 3-year median for EBT is -$13.0 million (2024), against an average of -$11.1 million.
  • The largest annual shift saw EBT skyrocketed 733.52% in 2024 before it tumbled 95.01% in 2025.
  • A 3-year view of EBT shows it stood at -$25.6 million in 2023, then increased by 3.2% to -$24.8 million in 2024, then soared by 36.37% to -$15.8 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's EBT are -$15.8 million (Q4 2025), $304000.0 (Q3 2025), and -$9.7 million (Q2 2025).